Estimating The Number of Relapsed And Refractory Indolent Lymphoma Patients Across Europe, Who Are Expected To Initiate A New Line of Therapy (LOT)
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.123
https://www.valueinhealthjournal.com/article/S1098-3015(17)30457-6/fulltext
Title :
Estimating The Number of Relapsed And Refractory Indolent Lymphoma Patients Across Europe, Who Are Expected To Initiate A New Line of Therapy (LOT)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30457-6&doi=10.1016/j.jval.2017.08.123
First page :
A418
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
104